700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Background: Recently, researches have expressed renewed interest in therapeutic effects of bupropion on the positive and negative symptoms in schizophrenics.
Aim & Objective: In current study, was designed a 12-week double-blind, parallel-groups to examine the comparative efficacy of bupropion compared to placebo for improving the positive and negative symptoms of schizophrenia.
Methods/Study Design: Eligible participants were 40 patients who met DSM-IV criteria for schizophrenia and were randomly assigned to the standard therapeutic dose of bupropion (150 mg/day for the first 3 days, followed by 300 mg/day) administered orally for a total of 8 weeks (n=20) or an identical appearing placebo tablet added to their usual medication regimen (n=20). The study endpoints were the scales of positive and negative symptoms of schizophrenia by the two scales for the assessment of positive symptoms (SAPS) and negative symptoms (SANS).
Results/Finding: : After the completion of treatment schedules, both groups demonstrated similar significant improvements in all positive symptoms, adjusted for baseline variables. However, it appeared that the avolition-apathy score of negative symptoms was reduced more in the group treated with bupropion compared to the placebo group.
Conclusion: Bupropion has potential efficacy for avolition-apathy as main negative symptoms in schizophrenics who were able to tolerate bupropion and complete 12-week bupropion treatment regimen. However, no change in positive symptoms may be essentially appeared.
placebo, bupropion, positive symptoms negative symptoms, schizophrenia